新辅助化疗联合放疗治疗Ⅲ-ⅣA期宫颈癌患者的临床疗效  

Clinical efficacy of neoadjuvant chemotherapy combined with radiotherapy in the treatment of patients with stage III-IVA cervical cancer

作　　者：郭东雅 李代红[1] 王昭辉[1] GUO Dongya;LI Daihong;WANG Zhaohui(Department of Obstetrics and Gynecology,the First People’s Hospital of Pingdingshan,Pingdingshan 467000,He’nan,China)

机构地区：[1]平顶山市第一人民医院妇产科,河南平顶山467000

出　　处：《癌症进展》2025年第8期892-894,906,共4页Oncology Progress

摘　　要：目的目的探讨新辅助化疗联合放疗治疗Ⅲ~ⅣA期宫颈癌患者的临床疗效。方法方法根据治疗方法的不同将83例Ⅲ~ⅣA期宫颈癌患者分为对照组(n=41,采取放疗)和观察组(n=42,采取新辅助化疗联合放疗)。比较两组患者的临床疗效、生活质量[生活质量综合评定问卷(GQOLI-74)]、不良反应发生情况及生存情况。结果结果观察组患者的疾病控制率、1年生存率均高于对照组,差异均有统计学意义(P﹤0.05)。治疗后,两组患者GQOLI-74各维度评分均高于本组治疗前,观察组患者GQOLI-74各维度评分均高于对照组,差异均有统计学意义(P﹤0.05)。两组患者不良反应总发生率比较,差异无统计学意义(P﹥0.05)。结论结论新辅助化疗联合放疗治疗Ⅲ~ⅣA期宫颈癌患者可提高临床疗效、生活质量及生存率,且具有一定的安全性。Objective To explore the clinical efficacy of neoadjuvant chemotherapy combined with radiotherapy in the treatment of patients with stage III-IVA cervical cancer.Method According to the different treatment methods,83 pa-tients with stage III-IVA cervical cancer were divided into control group(n=41,received radiotherapy)and observation group(n=42,received neoadjuvant chemotherapy combined with radiotherapy).The clinical efficacy,quality of life[ge-neric quality of life inventory-74(GQOLI-74)],adverse reactions and survival were compared between the two groups.Result The disease control rate and 1-year survival rate of observation group were higher than those of control group,and the differences were statistically significant(P<0.05).After treatment,the scores of all dimensions of GQOLI-74 in both groups were higher than those before treatment,and the scores of all dimensions of GQOLI-74 in observation group were higher than those in control group,the differences were statistically significant(P<0.05).There was no statistically significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion Neoadju-vant chemotherapy combined with radiotherapy can improve clinical efficacy,quality of life and survival rate in patients with stage III-IVA cervical cancer,and has certain safety.

关 键 词：新辅助化疗 放疗 宫颈癌 临床疗效 

分 类 号：R737.33[医药卫生—肿瘤]